[Nov. 9] D5 Seminar-Dr. Paul Liu (NIH/NHGRI)

November 7 2023

The "D5 Medical & Life Science Seminar" course will be offered by International Research Center for Medical Sciences (IRCMS). It will run from May 2023 to March 2024, with lectures given by scientists who are affiliated with IRCMS or in collaboration with researchers at IRCMS. The lectures will be given once a month, in English, and by leading scientists in the relevant research field. Students will be taught: 1) how normal physiological functions are maintained in the human body; 2) how these systems become abnormal under certain pathophysiologic conditions; 3) why stem cells are important in animal development and homeostasis; 4) how stem cell-based approaches can help us understand disease mechanisms and find potential cure for diseases related to stem cell malfunction (e.g., cancer, aging).

Anyone who wants to join is welcome.
For students who have registered for the course, please check your attendance in Moodle.

Date      : November 9th, 2023 (Thursday)
               

Format  : Online

Time      : 9:00 - 10:00 (JST)
               

Speaker : Dr. Paul Liu (NIH/NHGRI)
               

Title       :  RUNX1 in CBFB-MYH11 leukemia and familial platelet disorder

Abstract  :

We use genetic and genomic approaches to investigate the molecular mechanisms of leukemogenesis and hematopoiesis with the goal of translating our findings to enhance both the diagnosis and treatment of leukemia and other blood diseases. Most of our studies have been focused on two transcription factors, RUNX1 and CBFb, which form a heterodimer called core binding factor (CBF)1.  RUNX1 and CBFb regulate hematopoiesis at multiple stages and also play major roles in leukemia pathogenesis when they undergo gene rearrangement and fusion with partner genes. Understanding their roles during hematopoiesis is essential for our understanding of their involvement in leukemogenesis, as well as their roles in other hematologic diseases, such as familial platelet disorder with associated myeloid malignancies (FPDMM), which results from germline mutations in RUNX1.

References:

• Sood R, Kamikubo Y, Liu PP. Role of RUNX1 in hematological malignancies. Blood 129:2070-82, 2017. PMID: 28179279
• Zhen T, Cao Y, Ren G, Zhao L, Hyde RK, Lopez G, Feng D, Alemu L, Zhao K, Liu PP. RUNX1 and CBFb-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.  Blood 2020 https://doi.org/10.1182/blood.2020007747
• Accompanying commentary (https://ashpublications.org/blood/issue/136/21, https://doi.org/10.1182/blood.2020008802)
• Cunningham L*, *Merguerian M*, Calvo KR, Davis J, Deuitch NT, Dulau-Florea A, Patel N, Yu K, Sacco K, Bhattacharya S, Passi M, Ozkaya N, De Leon S, Chong S, Craft K, Diemer J, Bresciani E, O'Brien K, Andrews EJ, Park N, Hathaway L, Cowen EW, Heller T, Ryan K, Barochia A, Nghiem K, Niemela J, Rosenzweig S, Young DJ, Frischmeyer-Guerrerio PA, Braylan R, Liu PP. Natural history study of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy. Blood 2023 Sep 22;blood.2023019746. doi: 10.1182/blood.2023019746. Online ahead of print. PMID: 37738626
• Yu K, Deuitch N, Merguerian M, Cunningham L, Davis J, Bresciani E, Diemer J, Andrews E, Young A, Donovan F, Sood R, Craft K, Chong S, Chandrasekharappa S, Mullikin J, Liu PP. Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy. bioRxiv 2023 Jan 17;2023.01.17.524290. doi: 10.1101/2023.01.17.524290. Preprint